Who are Metformin + Testosterone Undecanoate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-testosterone-undecanoate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Metformin + Testosterone Undecanoate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin + Testosterone Undecanoate (Metformin + Testosterone Undecanoate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: biguanide + androgen replacement. Area: Endocrinology / Metabolic Disease.

phase 3 Combination therapy: biguanide + androgen replacement AMPK (metformin); androgen receptor (testosterone undecanoate) Endocrinology / Metabolic Disease Small molecule Live · refreshed every 30 min

Target snapshot

Metformin + Testosterone Undecanoate (Metformin + Testosterone Undecanoate) — Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Metformin improves insulin sensitivity and glucose metabolism while testosterone undecanoate restores androgen levels, together addressing metabolic dysfunction and hypogonadism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin + Testosterone Undecanoate TARGET	Metformin + Testosterone Undecanoate	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	phase 3	Combination therapy: biguanide + androgen replacement	AMPK (metformin); androgen receptor (testosterone undecanoate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: biguanide + androgen replacement class)

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin + Testosterone Undecanoate — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-testosterone-undecanoate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab